Abstract
Intrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding of EGFR-TKI resistance mechanisms in LUAD will potentially assist in formulating strategies to delay or overcome such resistance. Herein, it was observed that trefoil factor 3 (TFF3) is a crucial mediator of the LUAD EGFR-TKI response. TFF3 conferred intrinsic resistance to EGFR inhibition in LUAD by promotion of EGFR activation. TFF3 expression was also increased in acquired EGFR-TKI resistant LUAD, accompanied by reduced EGFR activation. YAP, a key mediator of the Hippo signaling, was positively regulated by TFF3 by post-transcriptional mechanisms and was responsible for acquired EGFR-TKI resistance mediated by TFF3. Inhibition of TFF3 by a small molecule inhibitor not only enhanced EGFR-TKI sensitivity in LUAD cells but also restored the sensitivity of acquired EGFR-TKI resistant LUAD cells to EGFR-TKIs in vitro and in vivo. These findings demonstrate a pivotal function of TFF3 in mediating both intrinsic and acquired EGFR-TKI resistance in LUAD and may offer a potential therapeutic mechanism for delaying or overcoming resistance to EGFR-TKIs.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: High TFF3 expression correlates with worse prognosis in LUAD patients and forced expression of TFF3 reduces EGFR-TKI sensitivity in LUAD cells via EGFR signaling.
Fig. 2: Depletion of TFF3 or inhibition of TFF3 with AMPC increases the sensitivity of LUAD to EGFR-TKIs.
Fig. 3: TFF3 expression is elevated in acquired EGFR-TKI resistant LUAD.
Fig. 4: Depletion of TFF3 or inhibition of TFF3 with AMPC restores the sensitivity of acquired EGFR-TKI resistant LUAD cells to EGFR-TKIs.
Fig. 5: Inhibition of TFF3 with AMPC decreases cancer cell proliferation, promotes apoptosis and restores EGFR-TKI sensitivity in acquired EGFR-TKI resistant LUAD xenografts.
Fig. 6: Inactivation of Hippo signaling pathway is required for acquired EGFR-TKI resistance.
Fig. 7: TFF3 inactivates Hippo signaling in acquired EGFR-TKI resistance.
Data availability
The data sets used in this study are available from the corresponding author on reasonable request.
References
Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017;8:50209–20.
ArticlePubMedPubMed CentralGoogle Scholar
Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med. 2004;10:481–6.
ArticlePubMedGoogle Scholar
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.
ArticlePubMedGoogle Scholar
Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473–81.
ArticlePubMedGoogle Scholar
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl J Med. 2018;378:113–25.
ArticlePubMedGoogle Scholar
Reita D, Pabst L, Pencreach E, Guerin E, Dano L, Rimelen V, et al. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers (Basel). 2021;13:4926.
Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66:7854–8.
ArticlePubMedGoogle Scholar
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521–8.
ArticlePubMedGoogle Scholar
Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl J Med. 2015;372:1689–99.
ArticlePubMedGoogle Scholar
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637–58.
ArticlePubMedGoogle Scholar
Zhou J, Zhou F, Xie H, Wu Y, Zhao J, Su C. An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report. Transl Lung Cancer Res. 2020;9:354–9.
ArticlePubMedPubMed CentralGoogle Scholar
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2:922–33.
ArticlePubMedPubMed CentralGoogle Scholar
Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, et al. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Mol Cancer Res. 2017;15:915–28.
ArticlePubMedGoogle Scholar
Shinohara S, Ichiki Y, Fukuichi Y, Honda Y, Kanoyama M, Taira A, et al. Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. J Thorac Dis. 2018;10:E526–E531.
ArticlePubMedPubMed CentralGoogle Scholar
Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE. Are trefoil factors oncogenic? Trends Endocrinol Metab. 2008;19:74–81.
ArticlePubMedGoogle Scholar
Thim L, May FE. Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci. 2005;62:2956–73.
ArticlePubMedPubMed CentralGoogle Scholar
Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, et al. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010;12:1041–53.
ArticlePubMedPubMed CentralGoogle Scholar
Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, et al. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 2014;16:429.
ArticlePubMedPubMed CentralGoogle Scholar
Poh HM, Chiou YS, Chong QY, Chen RM, Rangappa KS, Ma L, et al. Inhibition of TFF3 Enhances Sensitivity-and Overcomes Acquired Resistance-to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers (Basel). 2019;11:1528.
Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 2008;99:768–73.
ArticlePubMedPubMed CentralGoogle Scholar
Belle NM, Ji YB, Herbine K, Wei Y, Park J, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Communications. 2019;10:4408.
Chen RM, Chiou YS, Chong QY, Poh HM, Tan TZ, Zhang MY, et al. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. Int J Mol Sci. 2019;20:6215.
Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for Serum Levels of Trefoil Factor Family Proteins Can Improve Gastric Cancer Screening. Gastroenterology. 2011;141:837–U548.
ArticlePubMedGoogle Scholar
You ML, Chen YJ, Chong QY, Wu MM, Pandey V, Chen RM, et al. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget. 2017;8:39323–44.
ArticlePubMedPubMed CentralGoogle Scholar
Cheng F, Wang X, Chiou YS, He C, Guo H, Tan YQ, et al. Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death Dis. 2022;13:265.
ArticlePubMedPubMed CentralGoogle Scholar
Cui HY, Wang SJ, Song F, Cheng X, Nan G, Zhao Y, et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct Tar. 2021;6:268.
Zhang M, Wang B, Chong QY, Pandey V, Guo Z, Chen RM, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8:65.
ArticlePubMedPubMed CentralGoogle Scholar
Pandey V, Zhang X, Poh HM, Wang B, Dukanya D, Ma L, et al. Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival. ACS Pharm Transl Sci. 2022;5:761–73.
ArticleGoogle Scholar
Qu Y, Yang Y, Ma D, Xiao W. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep. 2012;27:1277–83.
ArticlePubMedGoogle Scholar
Wiede A, Jagla W, Welte T, Kohnlein T, Busk H, Hoffmann W. Localization of TFF3, a new mucus-associated peptide of the human respiratory tract. Am J Respir Crit Care Med. 1999;159:1330–5.
ArticlePubMedGoogle Scholar
Myers DJ, Wallen JM. Lung Adenocarcinoma. StatPearls Publishing, Treasure Island (FL). 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519578/.
Wang XN, Wang SJ, Pandey V, Chen P, Li Q, Wu ZS, et al. Trefoil Factor 3 as a Novel Biomarker to Distinguish Between Adenocarcinoma and Squamous Cell Carcinoma Med. 2015;94:e860.
Chong QY, You ML, Pandey V, Banerjee A, Chen YJ, Poh HM, et al. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma. Oncotarget. 2017;8:74188–208.
ArticlePubMedPubMed CentralGoogle Scholar
Kinoshita K, Taupin DR, Itoh H, Podolsky DK. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol. 2000;20:4680–90.
ArticlePubMedPubMed CentralGoogle Scholar
Taupin D, Wu DC, Jeon WK, Devaney K, Wang TC, Podolsky DK. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest. 1999;103:R31–38.
ArticlePubMedPubMed CentralGoogle Scholar
Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390–401.
ArticlePubMedPubMed CentralGoogle Scholar
Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H, et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Commun. 2016;474:154–60.
ArticlePubMedGoogle Scholar
Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, et al. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget. 2016;7:51922–33.
ArticlePubMedPubMed CentralGoogle Scholar
Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D, et al. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma. Cancer Med. 2021;10:1405–17.
ArticlePubMedPubMed CentralGoogle Scholar
Ghiso E, Migliore C, Ciciriello V, Morando E, Petrelli A, Corso S, et al. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia. 2017;19:1012–21.
ArticlePubMedPubMed CentralGoogle Scholar
Ma S, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;88:577–604.
ArticlePubMedGoogle Scholar
Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73–79.
ArticlePubMedPubMed CentralGoogle Scholar
Zhou B, Flodby P, Luo J, Castillo DR, Liu Y, Yu FX, et al. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Investig. 2018;128:970–84.
ArticlePubMedPubMed CentralGoogle Scholar
Hong SA, Jang SH, Oh MH, Kim SJ, Kang JH, Hong SH. Overexpression of YAP1 in mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival. Pathol Res Pr. 2018;214:335–42.
ArticleGoogle Scholar
Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. Sci Rep. 2018;8:271.
ArticlePubMedPubMed CentralGoogle Scholar
Yang YQ, Lin ZY, Lin QY, Bei WJ, Guo J. Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. Cell Death Dis. 2022;13:62.
Gao H, Korn JM, Ferretti S, Monahan JE, Wang YZ, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21:1318–25.
ArticlePubMedGoogle Scholar
Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17.
ArticlePubMedPubMed CentralGoogle Scholar
Sugihara T, Werneburg NW, Hernandez MC, Yang L, Kabashima A, Hirsova P, et al. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res. 2018;16:1556–67.
ArticlePubMedPubMed CentralGoogle Scholar
Huang W, Mao Y, Zhan Y, Huang J, Wang X, Luo P, et al. Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy. Oncol Lett. 2016;11:723–30.
ArticlePubMedGoogle Scholar
Zhou CW, Zhu YG, Lu B, Zhao WJ, Zhao XD. Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine. Oncol Lett. 2018;16:5466–72.
PubMedPubMed CentralGoogle Scholar
Atikcan S, Unsal E, Demirag F, Koksal D, Yilmaz A. Correlation between survivin expression and prognosis in non-small cell lung cancer. Resp Med. 2006;100:2220–6.
ArticleGoogle Scholar
Lu Y, Bian D, Zhang X, Zhang H, Zhu Z. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Mol Med Rep. 2021;23:48.
Cheong HT, Xu F, Choy CT, Hui CWC, Mok TSK, Wong CH. Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI. Oncol Lett. 2018;15:901–7.
PubMedGoogle Scholar
Song Y, Fu J, Zhou M, Xiao L, Feng X, Chen H, et al. Activated Hippo/Yes-Associated Protein Pathway Promotes Cell Proliferation and Anti-apoptosis in Endometrial Stromal Cells of Endometriosis. J Clin Endocrinol Metab. 2016;101:1552–61.
ArticlePubMedPubMed CentralGoogle Scholar
Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151:1457–73.
ArticlePubMedPubMed CentralGoogle Scholar
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479–87.
ArticlePubMedGoogle Scholar
Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.
ArticlePubMedPubMed CentralGoogle Scholar
Morito K, Nakamura J, Kitajima Y, Kai K, Tanaka T, Kubo H, et al. The value of trefoil factor 3 expression in predicting the long‑term outcome and early recurrence of colorectal cancer. Int J Oncol. 2015;46:563–8.
ArticlePubMedGoogle Scholar
Im S, Yoo C, Jung JH, Choi HJ, Yoo J, Kang CS. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis. Int J Med Sci. 2013;10:133–40.
ArticlePubMedGoogle Scholar
Braga Emidio N, Meli R, Tran HNT, Baik H, Morisset-Lopez S, Elliott AG, et al. Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite. J Med Chem. 2021;64:9484–95.
ArticlePubMedPubMed CentralGoogle Scholar
Storesund T, Hayashi K, Kolltveit KM, Bryne M, Schenck K. Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur J Oral Sci. 2008;116:135–40.
ArticlePubMedGoogle Scholar
Guo H, Tan YQ, Huang X, Zhang S, Basappa B, Zhu T, et al. Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma. Cancer Lett. 2023;579:216443.
ArticlePubMedGoogle Scholar
Rong X, Liang Y, Han Q, Zhao Y, Jiang G, Zhang X, et al. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. J Thorac Oncol. 2019;14:1766–83.
ArticlePubMedGoogle Scholar
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18:165.
ArticlePubMedPubMed CentralGoogle Scholar
Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, et al. DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. Oncogene. 2022;41:83–98.
ArticlePubMedGoogle Scholar
Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28–32.
ArticlePubMedGoogle Scholar
Wang F, Wang S, Wang Z, Duan J, An T, Zhao J, et al. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. J Exp Clin Cancer Res. 2012;31:65.
ArticlePubMedPubMed CentralGoogle Scholar
Calses PC, Crawford JJ, Lill JR, Dey A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends Cancer. 2019;5:297–307.
ArticlePubMedGoogle Scholar
Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. J Natl Cancer Inst. 2017;109:djx014.
Hsu PC, Yang CT, Jablons DM, You L. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancer. 2020;12:1361.
Zeng R, Dong J. The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers (Basel). 2021;13:318.
Lv L, Zhou X. Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential. MedComm (2020). 2023;4:e375.
ArticlePubMedGoogle Scholar
Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020;10:3622–35.
ArticlePubMedPubMed CentralGoogle Scholar
Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012;109:E2441–2450.
ArticlePubMedPubMed CentralGoogle Scholar
Li J, Wang R, Li M, Zhang Z, Jin S, Ma H. APIP regulated by YAP propels methionine cycle and metastasis in head and neck squamous cell carcinoma. Cancer Lett. 2024;588:216756.
ArticlePubMedGoogle Scholar
Zhang QR, Wang R, Xu L. Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review. Transl Cancer Res. 2023;12:3764–78.
Bui NL, Pandey V, Zhu T, Ma L, Basappa, Lobie PE. Bad phosphorylation as a target of inhibition in oncology. Cancer Lett. 2018;415:177–86.
ArticlePubMedGoogle Scholar
Zhang S, Deng Y, Xiang Y, Hu S, Qiu L, Zhang Y. Synergism and Antagonism of Two Distinct, but Confused, Nrf1 Factors in Integral Regulation of the Nuclear-to-Mitochondrial Respiratory and Antioxidant Transcription Networks. Oxid Med Cell Longev. 2020;2020:5097109.
ArticlePubMedPubMed CentralGoogle Scholar
Worlein JM, Baker K, Bloomsmith M, Coleman K, Koban TL. The Eighth Edition of the Guide for the Care and Use of Laboratory Animals (2011); Implications for Behavioral Management. Am J Primatol. 2011;73:98–98.
Google Scholar
Download references
Acknowledgements
The authors would like to thank Dr. Xiaoming Huang and Dr. Hui Guo for their valuable technical support. This work was supported by National Natural Science Foundation of China (82172618 and 82102768); the Shenzhen Key Laboratory of Innovative Oncotherapeutics (ZDSYS20200820165400003) (Shenzhen Science and Technology Innovation Commission), China; Shenzhen Development and Reform Commission Subject Construction Project ([2017] 1434), China; Universities Stable Funding Key Projects (WDZC20200821150704001), China; Guangdong Basic and Applied Basic Research Foundation (2020A1515111064), China; the Shenzhen Bay Laboratory, Oncotherapeutics (21310031), China; Overseas Research Cooperation Project (HW2020008) (Tsinghua Shenzhen International Graduate School), China; TBSI Faculty Start-Up Funds, China and Start-up Research Fund, BNU-HKBU United International College (UICR0700101-24), China.
Author information
Authors and Affiliations
Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, 518055, PR China
Shuwei Zhang, Yan Qin Tan, Vijay Pandey & Peter E. Lobie
Guangdong Provincial Key Laboratory IRADS and Food Science and Technology Program, Department of Life Sciences, BNU-HKBU United International College, Zhuhai, 519087, Guangdong, PR China
Yan Qin Tan
Shenzhen Bay Laboratory, Shenzhen, 518055, Guangdong, PR China
Xi Zhang, Tao Zhu & Peter E. Lobie
Labortory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore, 570005, India
Basappa Basappa
Department of Oncology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, PR China
Tao Zhu
Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, PR China
Tao Zhu
Authors
Shuwei Zhang
View author publications
You can also search for this author in PubMedGoogle Scholar
2. Yan Qin Tan
View author publications
You can also search for this author in PubMedGoogle Scholar
3. Xi Zhang
View author publications
You can also search for this author in PubMedGoogle Scholar
4. Basappa Basappa
View author publications
You can also search for this author in PubMedGoogle Scholar
5. Tao Zhu
View author publications
You can also search for this author in PubMedGoogle Scholar
6. Vijay Pandey
View author publications
You can also search for this author in PubMedGoogle Scholar
7. Peter E. Lobie
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
P.E.L., V.P. and S.Z. designed the study; Basappa synthesized AMPC; S.Z. and Y.Q.T. performed the experiments; S.Z., Y.Q.T., T.Z. and P.E.L. analyzed the data; X.Z. provided resources and cell lines; S.Z. wrote the draft; P.E.L. and Y.Q.T. revised the paper. All authors read and approved the final manuscript.
Corresponding authors
Correspondence to Vijay Pandey or Peter E. Lobie.
Ethics declarations
Competing interests
The authors declare the following competing financial interest(s): P.E.L. and T.Z. have previously consulted for Perseis Therapeutics Ltd. P.E.L. is named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. V.P., B.B., and P.E.L. are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof including US Patent 11,141,402). P.E.L. is an equity holder in Sinotar Pharmaceuticals Ltd., which currently holds PCT/SG2018/050277 and derivatives thereof including issued US Patent No. 11,141,402.
Consent for publication
All the authors agree to publish this paper.
Ethics approval and consent to participate
The authors confirm that all methods were performed in accordance with all relevant guidelines and regulations. All the animal experiments were approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Centre of Peking University Shenzhen Graduate School (permit YW); and ethical approval was obtained from Tsinghua Shenzhen International Graduate School (Number: 37, Year 2019). Informed consent for the use of the LUAD tissue samples and clinical data was obtained by Outdo Bio-tech Co., Ltd. (Shanghai, China).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
41388_2024_3244_MOESM1_ESM.doc
SI
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Zhang, S., Tan, Y.Q., Zhang, X. et al. TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma. Oncogene (2024). https://doi.org/10.1038/s41388-024-03244-5
Download citation
Received:12 April 2024
Revised:26 November 2024
Accepted:29 November 2024
Published:10 December 2024
DOI:https://doi.org/10.1038/s41388-024-03244-5
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative